<DOC>
	<DOCNO>NCT01403376</DOCNO>
	<brief_summary>Primary Objective : Assess antibody response influenza vaccine patient relapse form multiple sclerosis ( RMS ) treat teriflunomide compare reference population . Secondary Objectives : - Assess effect teriflunomide immunoglobulin level ; - Assess safety influenza vaccination patient RMS treat teriflunomide . The reference population define multiple sclerosis ( MS ) patient stable treatment interferon-β-1 . Antibody response measure use hemagglutination inhibition assay ( HIA ) hemagglutinin antigen represent stain H3N2 , H1N1 , B present influenza vaccine use .</brief_summary>
	<brief_title>Study Investigate Immune Response Influenza Vaccine Patients With Multiple Sclerosis Teriflunomide</brief_title>
	<detailed_description>The maximum duration study period participant approximatively 49 day break follow : - Screening period 21 day ; - Influenza vaccination Day 1 ; - Follow-up period 28 day ( ±2 day ) . MS treatment ( Teriflunomide interferon-β-1 ) continue course study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Male female patient &lt; 60 year old relapse multiple sclerosis ( RMS ) either treat least 6 month 7 14 mg teriflunomide one study LTS6048 LTS6050 , treat stable dose interferonβ1 least 6 month . Concomitant infectious pathology time vaccination ; MS relapse within 1 month vaccination ; Systemic corticosteroid within 1 month vaccination ; Any contraindication influenza vaccine ; Any vaccination within last 6 month ; Prior use investigational drug participation clinical trial within 1 year ( patient interferonβ1 ) ; Prior concomitant use ( minimum 1 year study entry ) cladribine , mitoxantrone , immunosuppressant agent azathioprine , cyclophosphamide , cyclosporin , methotrexate , mycophenolate , natalizumab ( Tysabri® ) , leflunomide fingolimod immunomodulator/immunosuppressant development ; Prior concomitant use glatiramer acetate within 1 year study entry ; Prior concomitant use intravenous immunoglobulin within 3 month study entry ; Pregnant breast feed woman ; Woman childbearing potential without adequate contraception . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>